宫腔镜粘连分离术后宫腔内灌注G-CSF促进子宫内膜生长的随机对照试验
这项两中心前瞻性双盲随机对照试验于2016年4月至2021年8月纳入245例中重度宫腔粘连综合征患者,按1:1随机分为G-CSF组和对照组,术后7天分别宫腔灌注300 µg(1.8 ml)G-CSF或1.8 ml生理盐水。结果显示G-CSF灌注可显著增加子宫内膜厚度(7.91±2.12 mm vs 7.22±2.04 mm,P=0.019),并改善累积妊娠率和活产率(P=0.017和P=0.042),但未显著降低粘连再形成率。
要点
- G-CSF灌注显著增加术后子宫内膜厚度(7.91±2.12 mm vs 7.22±2.04 mm,P=0.019)。
- G-CSF未显著降低宫腔粘连再形成率或粘连评分降低中位数。
- G-CSF组累积妊娠率和活产率随时间显著改善(P=0.017和P=0.042)。
核心结论
- 宫腔内灌注G-CSF可增加宫腔粘连综合征患者术后子宫内膜厚度,但不能预防宫腔粘连复发。
- 宫腔内灌注G-CSF可能作为宫腔粘连综合征患者增加子宫内膜厚度的有效辅助治疗。
研究设计与样本
- 两中心前瞻性双盲随机对照试验,2016年4月至2021年8月进行。
- 245例中重度宫腔粘连综合征患者按1:1随机分为G-CSF组和对照组。
- 229例纳入粘连复发分析,164例纳入妊娠结局分析。
- 所有患者接受首次宫腔镜粘连分离和球囊放置术,术后7天按随机分组宫腔灌注300 µg(1.8 ml)G-CSF或1.8 ml生理盐水,1-2个月后行二次宫腔镜检查。
主要发现
- 两组年龄、月经周期特征、妊娠史和术前宫腔粘连评分相似。
- 粘连再形成率和粘连评分降低中位数无统计学显著差异。
- G-CSF灌注显著改善子宫内膜厚度(7.91±2.12 mm vs 7.22±2.04 mm;P=0.019,差值95%CI:-1.26至-0.12)。
- G-CSF组累积妊娠率和活产率随时间显著改善(P=0.017和P=0.042)。
- 多因素logistic回归分析显示术后子宫内膜厚度是妊娠率和活产率的独立预后因素。
临床怎么用
- 作者认为宫腔内灌注G-CSF可能作为宫腔粘连综合征患者增加子宫内膜厚度的有效辅助治疗。
局限性
- 结果不能推广至年龄较大或无宫腔粘连综合征的患者,因研究对象为中重度宫腔粘连综合征且年龄<40岁。
- 生育分析纳入患者数量少可能导致结果偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Does intrauterine infusion of granulocyte colony-stimulating factor (G-CSF) prevent adhesion reformation and promote endometrial growth after hysteroscopic adhesiolysis? SUMMARY ANSWER: Intrauterine perfusion of G-CSF can increase endometrial thickness but does not prevent the recurrence of intrauterine adhesions (IUAs) in patients with Asherman syndrome (AS) after surgery. WHAT IS KNOWN ALREADY: Intrauterine infusion of G-CSF has been used in attempts to treat patients with recurrent miscarriage and an idiopathic thin endometrium for either fresh or frozen-thawed embryo transfer cycles but without uniform efficacy. There have been no reports on the effect of G-CSF on the recurrence of IUAs, endometrial regrowth or pregnancy results in specific populations with AS. STUDY DESIGN, SIZE, DURATION: This two-center prospective double-blind randomized controlled trial ran between April 2016 and August 2021. In it, 245 patients with moderate to severe AS were randomized to G-CSF and control groups at a 1:1 ratio; 229 women were included in the adhesion recurrence analysis; and 164 patients were analyzed for pregnancy outcomes. PARTICIPANTS/MATERIALS, SETTING, METHODS: All eligible patients received the first hysteroscopic adhesion separation and balloon placement procedure. Patients who met our inclusion and exclusion criteria were randomized after surgery. These patients returned for balloon removal and underwent intrauterine perfusion with 300 µg (1.8 ml) G-CSF or 1.8 ml normal saline according to randomization at 7 days after surgery. A second-look hysteroscopy was carried out 1-2 months later. The primary outcome was the rate of formation of new adhesions at the second hysteroscopy. The secondary outcomes included endometrial thickness in the periovulatory period after surgery, as well as the clinical pregnancy and live birth rates. MAIN RESULTS AND THE ROLE OF CHANCE: Age, menstrual cycle characteristics, pregnancy history and IUA score before surgery were similar between groups. There were no statistically significant differences in the adhesion reformation rate or median adhesion score reduction. However, G-CSF perfusion significantly improved endometrial thickness (7.91 ± 2.12 mm vs 7.22 ± 2.04 mm; P = 0.019, 95% CI for difference: -1.26 to -0.12), as well as cumulative pregnancy and live birth rate over time (P = 0.017 and P = 0.042). Furthermore, multivariate logistic regression analysis showed that postoperative endometrial thickness was an independent prognostic factor for pregnancy and live birth rates. LIMITATIONS, REASONS FOR CAUTION: These results cannot be extended to older patients or those without AS, as our subjects had moderate or severe AS and were aged <40 years. The low number of patients included in the fertility analysis could lead to biased results. WIDER IMPLICATIONS OF THE FINDINGS: Intrauterine perfusion of G-CSF could be an effective adjuvant therapy for patients with AS to increase endometrial thickness. STUDY FUNDING/COMPETING INTEREST(S): This study was supported by grants from the National Key Research and Development Program of China (2018YFC1004800), the National Natural Science Foundation of China (82001624 and 81871209), the Natural Science Foundation of Zhejiang Province (LQ20H040004) and the provincial and ministerial construction project of Zhejiang Province (2017 WKJ-ZJ-1721). The authors declare that they have no conflicts of interest regarding this work. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov (NCT02855632). TRIAL REGISTRATION DATE: 4 March 2016. DATE OF FIRST PATIENT’S ENROLMENT: 13 April 2016.
引用
- Zhang Y, Chen X, Chen S, et al. Intrauterine administration of G-CSF for promoting endometrial growth after hysteroscopic adhesiolysis: a randomized controlled trial. Hum Reprod. 2022. PMID: 35147195. doi:10.1093/humrep/deac023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。